Generalized pustular psoriasis (GPP) represents a severe, potentially fatal skin condition characterized by widespread sterile pustules and systemic inflammation. Recent evidence confirms that spesolimab for GPP provides a transformative treatment option for managing acute flares by targeting the interleukin-36 receptor (IL-36R). A prospective study recently evaluated the real-world safety and effectiveness of this monoclonal antibody over a six-month follow-up period.

The researchers analyzed 14 patients, comprising nine women and five men with a mean age of 39.1 years. They measured disease improvement using the Generalized Pustular Psoriasis Area and Severity Index (GPPASI). Initially, the cohort showed a mean baseline GPPASI of 3.61. However, this score dropped rapidly to 1.3 by day 7 and reached a low of 0.29 by the third month. This statistically significant decrease underscores the drug's ability to provide rapid clinical relief during flare-ups.

Clinical Impact of Spesolimab for GPP

Additionally, the study explored whether IL36RN mutation status influenced the therapeutic response. Notably, four patients carried the c.80T>C (p.L27P) mutation in a homozygous state. While these individuals responded slightly faster to the 900 mg intravenous infusion, the clinical outcomes converged for all patients by the third month. Consequently, spesolimab remains highly effective regardless of a patient's specific genetic profile, making it a versatile tool for dermatologists.

Safety results were equally encouraging. The clinical team observed no adverse events during the follow-up period, indicating excellent tolerability. Furthermore, most patients maintained sustained remission throughout the study. However, a small minority experienced a slight increase in GPPASI scores by month six. This specific observation suggests that while acute treatment is highly effective, some patients might require optimized long-term maintenance therapy to prevent future relapses.

Frequently Asked Questions

Does IL36RN mutation status affect the response to spesolimab?

While patients with IL36RN mutations may show a slightly faster initial response, the overall clinical efficacy is consistent across both mutation-positive and mutation-negative patients by three months of treatment.

How quickly does spesolimab work for GPP flares?

Spesolimab acts rapidly, with study data showing significant reductions in GPPASI scores as early as seven days after a single intravenous infusion.

Is spesolimab well-tolerated in a real-world setting?

Yes, this prospective study reported no adverse events over a six-month period, suggesting that spesolimab has a favorable safety profile for patients with GPP flares.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author or publisher. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Bahloul E et al. Spesolimab for generalized pustular psoriasis: A prospective study with a 6-month-follow-up. Clin Exp Dermatol. 2026 Apr 18. doi: undefined. PMID: 41999186.

Cardenas-Jesus A et al. Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience. Clin Exp Dermatol. 2025;50(5):442-449.

Bachelez H et al. Trial of Spesolimab for Generalized Pustular Psoriasis Flares. N Engl J Med. 2021;385(26):2431-2440.